ESPR
Price
$1.82
Change
-$0.03 (-1.62%)
Updated
Feb 21 closing price
Capitalization
495.94M
9 days until earnings call
PTPI
Price
$0.13
Change
-$0.01 (-7.69%)
Updated
Feb 21 closing price
Capitalization
3.26M
Ad is loading...

ESPR vs PTPI

Header iconESPR vs PTPI Comparison
Open Charts ESPR vs PTPIBanner chart's image
Esperion Therapeutics
Price$1.82
Change-$0.03 (-1.62%)
Volume$1.97M
Capitalization495.94M
Petros Pharmaceuticals
Price$0.13
Change-$0.01 (-7.69%)
Volume$6.89M
Capitalization3.26M
ESPR vs PTPI Comparison Chart
Loading...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTPI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ESPR vs. PTPI commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESPR is a Hold and PTPI is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (ESPR: $1.82 vs. PTPI: $0.13)
Brand notoriety: ESPR and PTPI are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ESPR: 48% vs. PTPI: 130%
Market capitalization -- ESPR: $495.94M vs. PTPI: $3.26M
ESPR [@Pharmaceuticals: Other] is valued at $495.94M. PTPI’s [@Pharmaceuticals: Other] market capitalization is $3.26M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.61B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ESPR’s FA Score shows that 1 FA rating(s) are green whilePTPI’s FA Score has 0 green FA rating(s).

  • ESPR’s FA Score: 1 green, 4 red.
  • PTPI’s FA Score: 0 green, 5 red.
According to our system of comparison, ESPR is a better buy in the long-term than PTPI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ESPR’s TA Score shows that 4 TA indicator(s) are bullish while PTPI’s TA Score has 4 bullish TA indicator(s).

  • ESPR’s TA Score: 4 bullish, 5 bearish.
  • PTPI’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ESPR is a better buy in the short-term than PTPI.

Price Growth

ESPR (@Pharmaceuticals: Other) experienced а -2.15% price change this week, while PTPI (@Pharmaceuticals: Other) price change was -57.34% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.14%. For the same industry, the average monthly price growth was +77.04%, and the average quarterly price growth was +50.35%.

Reported Earning Dates

ESPR is expected to report earnings on May 13, 2025.

PTPI is expected to report earnings on Mar 31, 2023.

Industries' Descriptions

@Pharmaceuticals: Other (-1.14% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ESPR($496M) has a higher market cap than PTPI($3.26M). ESPR YTD gains are higher at: -17.273 vs. PTPI (-68.266). PTPI has higher annual earnings (EBITDA): -8.76M vs. ESPR (-150.11M). ESPR has more cash in the bank: 82.2M vs. PTPI (18M). PTPI has less debt than ESPR: PTPI (8.69M) vs ESPR (266M). ESPR has higher revenues than PTPI: ESPR (116M) vs PTPI (6.99M).
ESPRPTPIESPR / PTPI
Capitalization496M3.26M15,224%
EBITDA-150.11M-8.76M1,713%
Gain YTD-17.273-68.26625%
P/E RatioN/AN/A-
Revenue116M6.99M1,661%
Total Cash82.2M18M457%
Total Debt266M8.69M3,062%
FUNDAMENTALS RATINGS
ESPR vs PTPI: Fundamental Ratings
ESPR
PTPI
OUTLOOK RATING
1..100
6696
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6598
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESPR's Valuation (33) in the Biotechnology industry is in the same range as PTPI (36) in the Medical Specialties industry. This means that ESPR’s stock grew similarly to PTPI’s over the last 12 months.

ESPR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PTPI (100) in the Medical Specialties industry. This means that ESPR’s stock grew similarly to PTPI’s over the last 12 months.

ESPR's SMR Rating (100) in the Biotechnology industry is in the same range as PTPI (100) in the Medical Specialties industry. This means that ESPR’s stock grew similarly to PTPI’s over the last 12 months.

ESPR's Price Growth Rating (65) in the Biotechnology industry is somewhat better than the same rating for PTPI (98) in the Medical Specialties industry. This means that ESPR’s stock grew somewhat faster than PTPI’s over the last 12 months.

ESPR's P/E Growth Rating (100) in the Biotechnology industry is in the same range as PTPI (100) in the Medical Specialties industry. This means that ESPR’s stock grew similarly to PTPI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ESPRPTPI
RSI
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 10 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
83%
Aroon
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTPI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEMKX39.75-0.09
-0.23%
Fidelity Emerging Markets Fund
AVENX12.08-0.04
-0.33%
Avantis® Emerging Markets Equity G
CUHAX11.12-0.16
-1.42%
Victory US 500 Enh Vol Wtd Idx A
FESAX10.19-0.32
-3.04%
First Eagle Small Cap Opportunity A
ADNRX16.55-1.00
-5.70%
American Beacon ARK Transfmt Innov R6

ESPR and

Correlation & Price change

A.I.dvisor tells us that ESPR and PTPI have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and PTPI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
-1.62%
PTPI - ESPR
29%
Poorly correlated
-5.59%
ZOM - ESPR
26%
Poorly correlated
-0.66%
EVO - ESPR
26%
Poorly correlated
-0.45%
VTRS - ESPR
25%
Poorly correlated
+1.72%
IXHL - ESPR
23%
Poorly correlated
+0.32%
More

PTPI and

Correlation & Price change

A.I.dvisor tells us that PTPI and ESPR have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PTPI and ESPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTPI
1D Price
Change %
PTPI100%
-5.59%
ESPR - PTPI
29%
Poorly correlated
-1.62%
RDHL - PTPI
26%
Poorly correlated
-2.86%
SNDL - PTPI
25%
Poorly correlated
+0.57%
ELTP - PTPI
24%
Poorly correlated
-1.92%
ACET - PTPI
23%
Poorly correlated
-2.66%
More